New combo before lung surgery shows promise in early trial

NCT ID NCT04933903

Recruiting now Disease control Sponsor: Brown University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether giving low-dose radiation along with two immunotherapy drugs (ipilimumab and nivolumab) before surgery can shrink tumors in people with stage IB to III non-small cell lung cancer. About 25 participants will receive the combination, then have surgery. The main goal is to see how many patients have a major or complete tumor response. Researchers are also monitoring safety and immune markers in blood and tissue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ipilimumab, Nivolumab, and low-dose stereotactic body radiation therapy (SBRT)
What this could lead to: If successful, this approach could improve tumor shrinkage before surgery, potentially leading to better long-term outcomes for lung cancer patients.
What could go wrong: This is a small, early-phase trial with only 25 participants, so results may not apply broadly. The combination of immunotherapy and radiation can cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Rhode Island Hospital
RECRUITING

Providence, Rhode Island, 02903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.